EP1545551A4 - INTERNAL EAR ADMINISTRATION OF GLUTAMATERGIC NEUROTRANSMISSION MODULATORS - Google Patents

INTERNAL EAR ADMINISTRATION OF GLUTAMATERGIC NEUROTRANSMISSION MODULATORS

Info

Publication number
EP1545551A4
EP1545551A4 EP02768820A EP02768820A EP1545551A4 EP 1545551 A4 EP1545551 A4 EP 1545551A4 EP 02768820 A EP02768820 A EP 02768820A EP 02768820 A EP02768820 A EP 02768820A EP 1545551 A4 EP1545551 A4 EP 1545551A4
Authority
EP
European Patent Office
Prior art keywords
internal ear
glutamatergic neurotransmission
ear administration
neurotransmission modulators
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02768820A
Other languages
German (de)
French (fr)
Other versions
EP1545551A1 (en
Inventor
Jean-Luc Puel
Remy Pujol
Yves Christen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Durect Corp
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Durect Corp filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of EP1545551A1 publication Critical patent/EP1545551A1/en
Publication of EP1545551A4 publication Critical patent/EP1545551A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP02768820A 2002-09-06 2002-09-06 INTERNAL EAR ADMINISTRATION OF GLUTAMATERGIC NEUROTRANSMISSION MODULATORS Withdrawn EP1545551A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/028519 WO2004022069A1 (en) 2002-09-06 2002-09-06 Delivery of modulators of glutamate-mediated neurotransmission to the inner ear

Publications (2)

Publication Number Publication Date
EP1545551A1 EP1545551A1 (en) 2005-06-29
EP1545551A4 true EP1545551A4 (en) 2008-10-22

Family

ID=31975588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02768820A Withdrawn EP1545551A4 (en) 2002-09-06 2002-09-06 INTERNAL EAR ADMINISTRATION OF GLUTAMATERGIC NEUROTRANSMISSION MODULATORS

Country Status (5)

Country Link
EP (1) EP1545551A4 (en)
JP (1) JP2006502158A (en)
AU (2) AU2002331830A1 (en)
CA (1) CA2497867A1 (en)
WO (1) WO2004022069A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
KR101189261B1 (en) * 2004-03-29 2012-10-09 앵스티띠 나셔날 드 라 쌍뜨 에 드 라 르셰르슈 메디깔 Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (en) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Treatment of phantom phenomena
JP2008531726A (en) * 2005-03-04 2008-08-14 ニューロシステック コーポレイション Improved gacyclidine formulation
JP5058163B2 (en) * 2005-07-22 2012-10-24 メドトロニック，インコーポレイテッド Small pump that discharges medicine
CN104840416A (en) * 2005-09-28 2015-08-19 奥里斯医学股份有限公司 Medicinal composition for treating internal-ear disease
KR101271263B1 (en) 2005-09-28 2013-06-07 아우리스 메디칼 아게 Pharmaceutical compositions for the treatment of inner ear disorders
US8267905B2 (en) 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
JP2010511595A (en) * 2006-07-31 2010-04-15 ニューロシステック コーポレイション Free base gacyclidine nanoparticles
EP2548552B1 (en) * 2007-09-12 2015-11-18 Merz Pharma GmbH & Co. KGaA Titration package for 1-amino-alkylcyclohexanes
DE102007063210A1 (en) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Medicines for the treatment of phantom phenomena
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CA2751761A1 (en) * 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
CA2732686C (en) * 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
PT3598971T (en) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc Dosage forms and therapeutic uses l-4-chlorokynurenine
US10500392B2 (en) 2016-08-24 2019-12-10 Cochlear Limited Monitoring stimulating assembly insertion
WO2023038778A1 (en) 2021-08-19 2023-03-16 Innovative Health Strategies Llc A smart self-activating wearable device for automatically injecting medicines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066652A (en) * 1995-08-02 2000-05-23 Tinnitus Forschungs-Und Entwicklungs Gmbh Method for treating diseases of the inner ear using adamantane derivatives
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066652A (en) * 1995-08-02 2000-05-23 Tinnitus Forschungs-Und Entwicklungs Gmbh Method for treating diseases of the inner ear using adamantane derivatives
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DENK D-M ET AL: "CAROVERINE IN TINNITUS TREATMENT A PLACEBO-CONTROLLED BLIND STUDY", ACTA OTO-LARYNGOLOGICA, SCANDINAVIAN UNIVERSITY PRESS, OSLO, NO, vol. 117, no. 6, 1 November 1997 (1997-11-01), pages 825 - 830, XP009043354, ISSN: 0001-6489 *
HIRBEC H ET AL: "GACYCLIDINE: A NEW NEUROPROTECTIVE AGENT ACTING AT THE N-METHYL-D-ASPARTATE RECEPTOR", CNS DRUG REVIEWS, BRANFORD, CT, US, vol. 2, no. 7, 1 January 2001 (2001-01-01), pages 172 - 198, XP008032600, ISSN: 1080-563X *
HOFFER M E ET AL: "Microdose gentamicin administration via the round window microcatheter: results in patients with Meniere's disease.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES OCT 2001, vol. 942, October 2001 (2001-10-01), pages 46 - 51, XP002494748, ISSN: 0077-8923 *
JACKSON LANCE E ET AL: "Chemical perfusion of the inner ear.", OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA JUN 2002, vol. 35, no. 3, June 2002 (2002-06-01), pages 639 - 653, XP009105345, ISSN: 0030-6665 *
LIU YE ET AL: "MK-801 protects against carbon monoxide-induced hearing loss", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 132, no. 2, 1995, pages 196 - 202, XP002494745, ISSN: 0041-008X *
OESTREICHERE ET AL: "Memantine suppresses the glutamatergic neurotransmission of mammalian inner hair cells", ORL, vol. 60, no. 1, 1 January 1998 (1998-01-01), BASEL. CH, pages 18 - 21, XP009105375 *
PARSONS C G ET AL: "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 6, 1 June 1999 (1999-06-01), pages 735 - 767, XP002279262, ISSN: 0028-3908 *
PUEL J-L ET AL: "TRAITEMENT DES ACOUPHENES NOUVELLES PERSPECTIVES//THE TREATMENT OF TINNITUS AURIUM NEW PERSPECTIVES", PRESSE MEDICALE, PRESSE MEDICALE, PARIS, FR, vol. 31, no. 24, 13 July 2002 (2002-07-13), pages 1137 - 1143, XP008054746, ISSN: 0755-4982 *
SAHLEY TONY L ET AL: "A biochemical model of peripheral tinnitus", HEARING RESEARCH, vol. 152, no. 1-2, February 2001 (2001-02-01), pages 43 - 54, XP002494746, ISSN: 0378-5955 *
See also references of WO2004022069A1 *
SEIDMAN M D: "GLUTAMATE ANTAGONISTS, STEROIDS, AND ANTIOXIDANTS AS THERAPEUTIC OPTIONS FOR HEARING LOSS AND TINNITUS AND THE USE OF AN INNER EAR DRUG DELIVERY SYSTEMS", INTERNATIONAL TINNITUS JOURNAL, BAD KISSINGEN, vol. 4, no. 2, 1 January 1998 (1998-01-01), pages 148 - 154, XP009043381, ISSN: 0946-5448 *
THOMSEN JENS ET AL: "Preliminary results of a new delivery system for gentamicin to the inner ear in patients with Meniere's disease", EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol. 257, no. 7, August 2000 (2000-08-01), pages 362 - 365, XP002494747, ISSN: 0937-4477 *

Also Published As

Publication number Publication date
JP2006502158A (en) 2006-01-19
EP1545551A1 (en) 2005-06-29
CA2497867A1 (en) 2004-03-18
AU2009233659A1 (en) 2009-11-26
WO2004022069A1 (en) 2004-03-18
AU2002331830A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
EP1545551A4 (en) INTERNAL EAR ADMINISTRATION OF GLUTAMATERGIC NEUROTRANSMISSION MODULATORS
EP1383518A4 (en) ORAL ADMINISTRATION OF MACROMOLECULES
PT1221918E (en) ADMINISTRATION OF SUB-TENON DRUGS
DK1207867T3 (en) Retarded oral pharmaceutical forms of administration with tramadol
NO20033143D0 (en) Pharmaceutical preparation
CY2018005I1 (en) ORAL PHARMACEUTICAL FORMS OF CLANTRIVINE
DE60024115D1 (en) PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES
DK1221919T3 (en) Ophthalmic drug administration device
EP1817003A4 (en) POROUS PHOTONIC CRYSTALS FOR THE OCULAR ADMINISTRATION OF DRUGS
DE69909135D1 (en) ORAL PREPARATION FOR FIGHT AGAINST MOUTH
PT1272468E (en) DERIVATIVES OF INDOLIN-2-ONA AND THEIR PREPARATION AND USE AS LIGHT OF RECEPTORS OF OCITOCIN
DK1622612T3 (en) Pharmaceutical formulation of the sodium salt of telmitarsan
NO20014738L (en) Tolperisone-containing pharmaceutical preparation for oral administration
EP1750677A4 (en) ORAL ADMINISTRATION SYSTEM OF THERAPEUTIC COMPOUND
NO20015149D0 (en) New pharmaceutical preparation
DE60036093D1 (en) ANTAGONISTS OF GARDOS CANAL
DE60203537D1 (en) 5HT1-RECEPTORAGONIST-CONTAINING MEDICAMENT
EP1632209A4 (en) PREPARATION OF ASEPTIC COMBINATION
NO20015148L (en) New pharmaceutical preparation
DE502004010644D1 (en) FLAVORED MEDICAMENT FORMULATIONS WITH IMPROVED PHARMACEUTICAL PROPERTIES
DK1467750T3 (en) Orodispersible pharmaceutical composition comprising perindopril
EE200100051A (en) Use of (+) - norcisapride or a pharmaceutically acceptable salt thereof substantially free of the corresponding (-) - stereoisomer and pharmaceutical composition
NO20043007L (en) Pharmaceutical suspension for oral administration
EE200200554A (en) Use of galantamine or a pharmaceutically acceptable salt thereof
NO20015104D0 (en) New pharmaceutical preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050401

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Owner name: CHRISTEN, YVES

Owner name: PUJOL, REMY

Owner name: PUEL, JEAN-LUC

Owner name: DURECT CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20080923

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/16 20060101ALI20080912BHEP

Ipc: A61K 31/553 20060101ALI20080912BHEP

Ipc: A61K 31/66 20060101AFI20040323BHEP

17Q First examination report despatched

Effective date: 20090210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RE

Owner name: DURECT CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110531